18.12USD+4.32%Mkt Cap: 3.00B USDP/E: —Last update: 2026-05-26
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap3.00B USD
Enterprise Value2.07B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-446.21M USD
Revenue/Share—
Last Price18.12 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees263
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.77
PEG—
EV/EBITDA-4.41
EV/Revenue—
P/S—
P/B2.95
EPS (TTM)-3.15
EPS (Forward)-3.01
52W Range
8.06059% of range25.00
52W High25.00 USD
52W Low8.060 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-45.90%
ROA-37.59%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-403.21M USD
CapEx (TTM)20.71M USD
FCF Margin—
FCF Yield-9.76%
Net Debt-803.48M USD
Net Debt/EBITDA1.71
Balance Sheet
Debt/Equity0.17
Current Ratio19.92
Quick Ratio18.97
Book Value/Sh5.893 USD
Cash/Share5.881 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)38.19 USD
Target Range16.00 USD – 50.00 USD
# Analysts16
Ownership
Shares Out.165.31M
Float164.76M
Insiders0.28%
Institutions115.45%
Short Interest
Short Ratio11.7d
Short % Float16.66%
Short % Out.12.55%
Shares Short20.73M
Short (prev mo.)20.47M
Technical
SMA 5018.26 (-0.8%)
SMA 20017.12 (+5.8%)
Beta1.08
S&P 52W Chg28.31%
Avg Vol (30d)1.62M
Avg Vol (10d)1.38M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—